Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Adenocarcinoma of the Pancreas
- Advanced Cancer
- Digestive System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Endocrine System Diseases
- Pancreatic Cancer
- Pancreatic Diseases
- Pancreatic Neoplasms
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Supportive Care
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
To assess the effect of Ocoxin-Viusid® on the quality of life of patients with advanced pancreatic adenocarcinoma. To evaluate the effect of Ocoxin-Viusid® on the quality of life of patients. To evaluate the influence of Ocoxin-Viusid® on tolerance to onco-specific therapy. Identify the changes that...
To assess the effect of Ocoxin-Viusid® on the quality of life of patients with advanced pancreatic adenocarcinoma. To evaluate the effect of Ocoxin-Viusid® on the quality of life of patients. To evaluate the influence of Ocoxin-Viusid® on tolerance to onco-specific therapy. Identify the changes that occur in the nutritional status of patients receiving the supplement. To evaluate the toxicity of Ocoxin-Viusid® in combination with chemotherapy in patients with advanced pancreatic adenocarcinoma.
Tracking Information
- NCT #
- NCT03717298
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon